proteolyt
cleavag
picornavir
polyprotein
essenti
viral
replic
therefor
viral
proteas
attract
target
antivir
therapi
assay
avail
test
proteolyt
activ
proteas
perform
vitro
use
heterolog
express
proteas
peptid
substrat
deal
disadvantag
associ
vitro
assay
modifi
cellbas
proteas
assay
picornaviru
proteas
assay
base
induct
express
firefli
luciferas
report
chimer
transcript
factor
viral
proteas
cleavag
site
insert
bind
domain
activ
domain
firefli
luciferas
express
depend
cleavag
transcript
factor
viral
proteas
biosaf
assay
enabl
test
effect
compound
proteas
activ
cell
circumv
need
infect
design
assay
proteas
pro
variou
enterovirus
well
virus
sever
picornaviru
genera
show
assay
amen
use
highthroughput
set
furthermor
show
spectrum
activ
pro
inhibitor
rupintrivir
encompass
enteroviru
pro
also
pro
footandmouth
diseas
viru
fmdv
aphthoviru
contrari
compound
analogu
effect
fmdv
pro
activ
provid
structur
explan
picornavirus
small
positivesens
rna
virus
singl
open
read
frame
divid
three
region
encod
structur
protein
encod
nonstructur
protein
virus
region
preced
small
leader
l
protein
viral
polyprotein
cleav
viral
proteas
result
releas
viral
protein
stabl
precursor
picornavirus
proteas
pro
respons
major
cleavag
within
viral
polyprotein
picornaviru
genera
encod
addit
proteas
pro
express
member
genu
enteroviru
cleav
region
l
pro
express
aphthoviru
erboviru
member
autocatalyt
cleav
c
terminu
addit
function
polyprotein
process
viral
proteas
target
varieti
host
protein
effici
viru
replic
includ
protein
involv
translat
transcript
immun
signal
nucleocytoplasm
traffic
eg
enteroviru
pro
aphthoviru
l
pro
impair
capdepend
translat
cleavag
initi
factor
lead
translat
host
shutoff
devaney
et
al
krausslich
et
al
lloyd
et
al
medina
et
al
cleavag
fmdv
pro
poli
bind
protein
enteroviru
pro
pro
also
contribut
host
shutoff
joachim
et
al
li
et
al
viral
proteas
provid
attract
target
antivir
therapi
picornavirus
essenti
role
viru
replic
cycl
absenc
cellular
homologu
tong
yet
antivir
therapi
approv
treat
picornaviru
infect
human
pathogen
found
genu
enteroviru
eg
polioviru
pv
coxsackieviru
enteroviru
human
rhinoviru
hrv
virus
caus
varieti
diseas
includ
acut
flaccid
paralysi
asept
mening
respiratori
infect
handfootandmouth
diseas
highli
contagi
footandmouth
diseas
viru
fmdv
aphthoviru
member
one
import
anim
pathogen
caus
outbreak
among
livestock
enorm
econom
impact
compound
also
known
rupintrivir
develop
potent
inhibitor
hrv
pro
irrevers
peptidomimet
bunsatur
ester
studi
reveal
also
abl
inhibit
replic
enterovirus
de
palma
et
al
lee
et
al
patick
et
al
tsai
et
al
howev
clinic
develop
halt
limit
activ
clinic
trial
natur
hrv
infect
patick
et
al
also
known
compound
analogu
improv
oral
bioavail
dragovich
et
al
display
antivir
activ
vitro
safe
welltoler
vivo
clinic
develop
discontinu
patick
et
al
recent
report
synthesi
seri
pro
inhibitor
like
peptid
bunsatur
ester
tan
et
al
seri
compound
potent
inhibitor
antivir
activ
pv
echoviru
hrv
tan
et
al
current
assay
avail
test
proteolyt
activ
mostli
perform
vitro
use
heterolog
express
proteas
peptid
substrat
howev
cellfre
assay
compound
test
drawback
first
compound
abl
inhibit
proteolyt
activ
assay
may
unabl
cross
plasma
membran
secondli
vitro
assay
unabl
assess
cell
toxic
thirdli
compound
requir
cellular
activ
identifi
hit
noncellbas
assay
deal
issu
adapt
cellbas
assay
develop
previous
pro
fig
lee
et
al
extend
assay
multipl
picornaviru
pro
appli
assay
test
spectrum
pro
inhibitor
demonstr
cellbas
proteas
assay
easi
biosaf
assay
test
proteas
activ
effect
inhibitor
amen
use
highthroughput
setup
monkey
kidney
cell
hela
cell
babi
hamster
kidney
cell
cultur
dmem
fc
penicillinstreptomycin
co
cultur
medium
suppplement
mgml
geneticin
sulphat
cell
deriv
human
hepatocellular
carcinoma
cell
constitut
express
rna
polymeras
schultz
et
al
plasmid
pbind
pact
deriv
mammalian
twohybrid
system
promega
produc
ligat
sequenc
amplifi
pact
xbai
noti
site
multipl
clone
site
pbind
subsequ
use
clone
proteas
construct
use
sali
mlui
site
mutagenesi
perform
use
quikchang
ii
sitedirect
mutagenesi
kit
agil
construct
insert
egfpcod
sequenc
amplifi
clontech
ncoi
ppumi
restrict
site
templat
primer
use
pcr
shown
supplementari
tabl
compound
synthes
describ
previous
tan
et
al
kind
gift
pfizer
compound
stock
dissolv
dmso
store
cell
seed
plate
next
day
medium
replac
compoundcontain
medium
cell
plate
plate
cotransfect
ng
proteas
construct
ng
use
fugen
accord
manufactur
instruct
plate
ng
plasmid
transfect
use
fugen
next
day
cell
harvest
lysi
buffer
mm
trishcl
mm
nacl
mm
edta
supplement
complet
proteas
inhibitor
cocktail
roch
ad
cell
pellet
cell
lysat
underw
two
round
vortex
incub
follow
centrifug
rpm
laemmli
ad
supernat
protein
separ
sdspage
polyacrylamid
gel
analysi
fusion
protein
fragment
polyacrylamid
gel
analysi
cleavag
protein
detect
use
mous
monoclon
antibodi
clontech
rabbit
polyclon
antibodi
bethyl
laboratori
rat
antitubulin
alpha
antibodi
abd
serotec
follow
appropri
monoclon
irdy
secondari
antibodi
licor
bioscienc
imag
done
odyssey
system
cell
seed
plate
next
day
subconflu
monolay
transfect
ng
proteas
construct
ng
report
plasmid
use
fugen
transfect
mix
ad
cell
medium
replac
dmsoor
compoundcontain
medium
h
cell
lyse
passiv
lysi
buffer
luciferas
activ
measur
dualglo
luciferas
assay
system
promega
experi
egfp
readout
experi
perform
describ
except
transfect
instead
cell
incub
h
imag
evo
fl
digit
fluoresc
microscop
amg
cell
fix
permeabil
stain
antibodi
check
similar
transfect
effici
graphpad
prism
use
statist
analysi
ec
valu
calcul
use
nonlinear
regress
set
valu
obtain
inact
mutant
untreat
wt
construct
top
bottom
constraint
respect
z
factor
calcul
valu
per
condit
use
follow
formula
z
sd
dmso
sd
mean
dmso
mean
multicycl
cpereduct
assay
perform
describ
previous
de
palma
et
al
gori
et
al
strain
nanci
infecti
clone
test
cell
fmdv
strain
manisa
cell
gori
et
al
wessel
et
al
short
cell
seed
plate
treat
next
day
serial
dilut
compound
infect
viru
low
moi
threeday
incub
cell
viabil
measur
mt
assay
aqueou
one
solut
cell
prolifer
assay
promega
dmso
concentr
use
ec
valu
determin
compound
assay
cell
cell
respect
dmso
concentr
advers
effect
cell
moleculardock
studi
perform
use
flexibl
dock
program
fleksi
nabuur
et
al
crystal
structur
fmdv
pro
complex
peptid
substrat
zunszain
et
al
pdb
id
solv
resolut
use
receptor
structur
structur
prepar
dock
remov
peptid
complex
subsequ
hydrogen
atom
ad
structur
posit
optim
use
yasara
program
http
wwwyasaraorg
otherwis
default
paramet
describ
previous
appli
nabuur
et
al
principl
proteas
assay
induct
firefli
luciferas
fluc
express
report
plasmid
absenc
proteolyt
activ
viral
proteas
fig
express
report
plasmid
regul
transcript
factor
compos
dnabind
domain
transactiv
domain
domain
insert
part
polyprotein
contain
pro
neighbor
cleavag
site
pro
proteolyt
activ
pro
lead
cleavag
chimer
protein
pro
cleavag
site
consequ
transcript
factor
lack
domain
fluc
express
howev
case
inact
proteas
proteolyt
cleavag
occur
fulllength
fusion
protein
transactiv
express
fluc
renilla
luciferas
rluc
independ
express
differ
promot
plasmid
express
proteas
construct
serv
measur
transfect
effici
indirectli
cell
viabil
test
whether
pro
proteas
assay
function
analyz
protein
produc
upon
overexpress
proteas
construct
western
blot
use
antibodi
cell
transfect
control
pbind
report
run
kda
kda
detect
respect
fig
overexpress
pro
band
migrat
slightli
slower
appear
correspond
fragment
produc
cleavag
fusion
protein
pro
upon
treatment
band
molecular
mass
ie
kda
detect
cell
transfect
pro
construct
render
inact
mutat
catalyt
site
lee
et
al
demonstr
uncleav
fulllength
product
cell
transfect
pro
also
express
protein
molecular
mass
correspond
predict
size
indic
cleavag
complet
block
presenc
lm
notwithstand
data
show
suitabl
assay
determin
pro
activ
determin
whether
pro
cleavag
activ
reflect
luciferas
level
produc
measur
fluc
rluc
activ
cell
cotransfect
pro
report
plasmid
treatment
lm
result
increas
fluc
level
compar
untreat
suggest
transactiv
report
plasmid
revers
correl
pro
activ
fig
left
panel
level
fluc
obtain
upon
similar
obtain
inact
mutant
pro
rluc
level
affect
catalyt
activ
pro
fig
right
panel
flucrluc
ratio
use
correct
possibl
differ
transfect
effici
test
rang
concentr
observ
dosedepend
increas
flucrluc
ratio
fig
concentr
lm
flucrluc
ratio
similar
level
observ
inact
mutant
observ
cleavag
occur
presenc
lm
fig
indic
cleavag
need
complet
inhibit
fluc
level
maxim
nevertheless
ec
valu
lm
ci
lm
pro
rang
ec
valu
lm
ci
lm
observ
cpereduct
multicycl
assay
use
tabl
suggest
proteas
assay
good
indic
potenc
inhibitor
viru
infect
togeth
result
show
cellbas
proteas
assay
suitabl
measur
proteas
activ
effect
proteas
inhibitor
mutat
assess
whether
assay
suffici
qualiti
use
highthroughput
set
calcul
z
factor
zhang
et
al
assay
z
factor
p
consid
excel
candid
highthroughput
screen
end
cell
cotransfect
pro
treat
dmso
neg
control
lm
posit
control
yield
z
factor
use
logtransform
fluc
valu
use
valu
correct
per
sampl
transfect
effici
ie
flucrluc
ratio
indic
assay
excel
use
highthroughput
screen
data
shown
fig
keep
measur
cost
low
great
import
largescal
test
therefor
test
whether
possibl
use
gfp
readout
elimin
need
reagent
measur
proteas
activ
gfp
signal
report
could
detect
cell
cotransfect
pro
wherea
gfp
visibl
upon
incub
upon
express
catalyticsit
mutant
pro
fig
result
demonstr
assay
use
highthroughput
test
enabl
us
determin
spectrum
potenti
proteas
inhibitor
design
equival
pro
construct
repr
hav
cleavag
fusion
protein
confirm
western
blot
data
shown
test
inhibitori
activ
pro
inhibitor
picornaviru
proteas
anticip
express
fluc
absenc
compound
compar
observ
pro
pro
construct
although
level
somewhat
higher
case
safv
hpev
hav
fig
rluc
activ
decreas
cell
express
fmdv
pro
fusion
protein
supplementari
fig
possibl
result
cleavag
pro
li
et
al
therefor
fluc
valu
use
data
analysi
instead
flucrluc
ratio
fluc
express
induc
upon
treatment
lm
cell
transfect
enteroviru
pro
construct
fig
left
panel
contrast
effect
observ
report
activ
upon
express
construct
emcv
safv
hpev
hav
pro
suggest
proteas
insensit
predict
proteas
assay
lm
display
signific
activ
emcv
safv
growth
curv
emcv
safv
supplementari
fig
remark
increas
fluc
express
cell
express
fmdv
pro
similar
level
observ
catalyt
inact
fmdv
pro
grubman
et
al
data
indic
fmdv
pro
sensit
proteas
inhibitor
similar
spectrum
activ
effect
fmdv
pro
activ
elabor
test
fmdv
pro
construct
concentr
seri
illustr
compound
less
potent
fmdv
fig
c
tabl
line
origin
design
enterovirus
fig
inhibit
enteroviru
pro
fmdv
pro
display
activ
enteroviru
pro
fmdv
pro
cell
cotransfect
construct
indic
proteas
report
treat
lm
next
day
luciferas
level
measur
display
fluc
level
b
c
inhibit
fmdv
pro
albeit
lower
potenc
pro
cell
cotransfect
fmdv
pro
construct
treat
rang
concentr
b
c
dash
line
repres
valu
obtain
respect
inact
mutant
upper
dash
line
valu
obtain
untreat
wt
construct
lower
dash
line
experi
perform
triplic
valu
repres
mean
fluc
sd
abl
inhibit
fmdvinduc
cpe
cell
multicycl
cpereduct
assay
ec
valu
lm
respect
indic
pro
inhibit
impair
replic
fmdv
tabl
sensit
fmdv
pro
led
us
test
whether
proteas
also
suscept
oral
bioavail
analog
remark
compound
display
littl
inhibitori
activ
toward
fmdv
pro
activ
pro
compar
observ
fig
tabl
rational
differ
potenc
toward
fmdv
pro
util
comput
model
techniqu
explain
observ
differ
inhibitori
activ
fig
toward
fmdv
pro
induc
fit
dock
use
predict
bind
mode
nabuur
et
al
potent
inhibitor
fmdv
pro
three
compound
fmdv
pro
recent
crystal
structur
fmdv
pro
complex
peptid
substrat
fig
zunszain
et
al
reveal
socal
bribbon
separ
subsit
proteas
slightli
longer
fmdv
pro
compar
proteas
exampl
seen
complex
pro
fig
sweeney
et
al
model
gener
suggest
interact
loop
mainli
respons
observ
select
profil
three
compound
assay
fig
show
obtain
model
bound
fmdv
pro
bribbon
highlight
blue
model
suggest
extens
tight
hydrophob
interact
posit
bribbon
fmdv
pro
ring
closur
present
posit
predict
clash
bribbon
fmdv
pro
provid
rational
observ
inact
toward
fmdv
pro
intermedi
potenc
compar
contain
tbutyl
ether
serin
side
chain
introduc
steric
bulk
compar
allow
flexibl
compar
potenti
explain
observ
intermedi
activ
studi
develop
assay
measur
proteas
activ
pro
variou
enterovirus
well
picornavirus
fig
base
principl
describ
previous
pro
lee
et
al
appli
assay
test
spectrum
activ
three
pro
inhibitor
major
advantag
assay
cellbas
contrast
proteas
assay
avail
consequ
compound
penetr
plasma
membran
advers
cellular
effect
select
search
proteas
inhibitor
anoth
advantag
assay
depend
increas
readout
signal
upon
inhibit
proteas
activ
preclud
identif
falseposit
hit
basi
aspecif
reduct
report
activ
toxic
also
compound
zunszain
et
al
c
pro
complex
orang
bribbon
highlight
red
gener
model
fmdv
pro
complex
bribbon
highlight
blue
interpret
refer
color
figur
legend
reader
refer
web
version
articl
requir
cellular
activ
accur
evalu
noncellbas
assay
natur
cellbas
assay
allow
easi
expans
rang
proteas
contrast
vitro
assay
requir
product
recombin
enzym
timeconsum
potenti
cumbersom
assay
could
also
appli
proteas
plusstrand
rna
virus
hepat
c
viru
dengu
viru
sar
coronaviru
one
exampl
cellbas
assay
would
advantag
pro
dengu
viru
famili
flavivirida
proteas
activ
commonli
test
construct
polypeptid
chain
cofactor
proteas
domain
link
nonapeptid
linker
optim
activ
construct
vitro
requir
high
ph
potenti
affect
proton
state
compound
henc
falseposit
falseneg
hit
screen
nobl
et
al
assay
preferenti
suitabl
use
highthroughput
set
show
assay
excel
use
highthroughput
set
exemplifi
z
factor
pro
fig
would
advis
also
test
assay
revers
proteas
inhibitor
appli
highthroughput
screen
confirm
assay
also
identifi
inhibitor
sever
adapt
optim
assay
use
largescal
screen
may
possibl
assay
may
downscal
format
save
materi
also
provid
proof
principl
use
gfp
readout
instead
fluc
fig
although
report
less
sensit
costeffici
addit
cell
line
stabl
construct
induc
may
use
avail
express
construct
wide
rang
picornaviru
pro
enabl
us
test
spectrum
activ
pro
inhibitor
show
compound
inhibit
pro
enteroviru
test
ie
pv
effect
process
pro
emcv
safv
hpev
hav
recent
public
report
inhibit
hav
replic
straindepend
also
found
effect
strain
use
debe
et
al
interestingli
compound
inhibit
pro
fmdv
albeit
lower
potenc
pro
test
multicycl
cpereduct
assay
reveal
assay
accur
predict
compound
possess
antivir
activ
studi
progress
shown
inhibit
fmdv
pro
vitro
fret
assay
use
fluorogen
substrat
recombin
pro
ic
lm
kim
et
al
corrobor
find
assay
present
insight
develop
may
help
tool
design
potent
proteas
inhibitor
fmdv
highli
contagi
zoonot
viru
caus
outbreak
enorm
econom
impact
conclus
present
proteas
assay
enabl
measur
proteas
activ
inhibitori
activ
compound
cellular
environ
current
expand
assay
proteas
viru
famili
